Evaluation of the Effects of Meal Type and Acid‐Reducing Agents on the Pharmacokinetics of Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor Agonist

Author:

Weber Elijah J.1,Younis Islam R.1,Wang Lulu1,Xiao Deqing1,Barchuk William T.1,Othman Ahmed A.1

Affiliation:

1. Gilead Sciences, Inc. Foster City CA USA

Abstract

AbstractCilofexor is a nonsteroidal farnesoid X receptor agonist being developed in combination with firsocostat/semaglutide for the treatment of nonalcoholic steatohepatitis. This phase 1 study evaluated the effects of food and acid‐reducing agents (ARAs) on the pharmacokinetics of cilofexor (100‐ or 30‐mg fixed‐dose combination with firsocostat) in healthy participants. Cohorts 1 (n = 20, 100 mg) and 2 (n = 30, 30 mg) followed a 3‐period, 2‐sequence crossover design and evaluated effects of light‐fat and high‐fat meals. Cohort 3 (n = 30, 100 mg fasting) followed a 2‐period, 2‐sequence crossover design and evaluated the effects of a 40‐mg single dose of famotidine. Cohort 4 (n = 18, 100 mg) followed a 3‐period, 2‐sequence crossover design and evaluated the effects of a 40‐mg once‐daily regimen of omeprazole administered under fasting conditions or following a light‐fat meal. Administration with light‐fat or high‐fat meals resulted in no change and an ∼35% reduction in cilofexor AUC, respectively, relative to the fasting conditions. Under fasting conditions, famotidine increased cilofexor AUC by 3.2‐fold and Cmax by 6.1‐fold, while omeprazole increased cilofexor AUC by 3.1‐fold and Cmax by 4.8‐fold. With a low‐fat meal, omeprazole increased cilofexor exposure to a lesser extent (Cmax 2.5‐fold, AUC 2.1‐fold) than fasting conditions. This study suggests that caution should be exercised when cilofexor is administered with ARAs under fed conditions; coadministration of cilofexor (100 or 30 mg) with ARAs under fasting conditions is not recommended with the current clinical trial formulations.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3